WallStreetZenWallStreetZen

NASDAQ: VRAX
Virax Biolabs Group Ltd Stock

$0.96+0.13 (+15.66%)
Updated Feb 21, 2024
VRAX Price
$0.96
Fair Value Price
$0.81
Market Cap
$1.75M
52 Week Low
$0.74
52 Week High
$16.00
P/E
-0.33x
P/B
0.28x
P/S
72.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$79.30k
Earnings
-$6.92M
Gross Margin
11.4%
Operating Margin
-8,710.56%
Profit Margin
-8,730.7%
Debt to Equity
0.15
Operating Cash Flow
-$5M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

VRAX Overview

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VRAX ($0.96) is overvalued by 19.73% relative to our estimate of its Fair Value price of $0.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRAX ($0.96) is not significantly undervalued (19.73%) relative to our estimate of its Fair Value price of $0.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRAX due diligence checks available for Premium users.

Be the first to know about important VRAX news, forecast changes, insider trades & much more!

VRAX News

Valuation

VRAX fair value

Fair Value of VRAX stock based on Discounted Cash Flow (DCF)
Price
$0.96
Fair Value
$0.81
Overvalued by
19.24%
VRAX ($0.96) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRAX ($0.96) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VRAX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.33x
Industry
16.04x
Market
28.8x

VRAX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
5.97x
VRAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VRAX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
VRAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$7.0M
Liabilities
$919.0k
Debt to equity
0.15
VRAX's short-term assets ($5.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRAX's short-term assets ($5.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
VRAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VRAX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VRAX$1.75M+15.87%-0.33x0.28x
WINT$1.72M+3.08%-0.02x0.23x
SXTP$1.80M-0.32%N/A0.27x
ALLR$1.83M-2.20%-0.00x-0.54x
PHIO$1.83M-1.32%-0.09x0.25x

Virax Biolabs Group Stock FAQ

What is Virax Biolabs Group's quote symbol?

(NASDAQ: VRAX) Virax Biolabs Group trades on the NASDAQ under the ticker symbol VRAX. Virax Biolabs Group stock quotes can also be displayed as NASDAQ: VRAX.

If you're new to stock investing, here's how to buy Virax Biolabs Group stock.

What is the 52 week high and low for Virax Biolabs Group (NASDAQ: VRAX)?

(NASDAQ: VRAX) Virax Biolabs Group's 52-week high was $16.00, and its 52-week low was $0.74. It is currently -93.98% from its 52-week high and 30.27% from its 52-week low.

How much is Virax Biolabs Group stock worth today?

(NASDAQ: VRAX) Virax Biolabs Group currently has 1,811,540 outstanding shares. With Virax Biolabs Group stock trading at $0.96 per share, the total value of Virax Biolabs Group stock (market capitalization) is $1.75M.

Virax Biolabs Group stock was originally listed at a price of $182.00 in Jul 21, 2022. If you had invested in Virax Biolabs Group stock at $182.00, your return over the last 1 years would have been -99.47%, for an annualized return of -99.47% (not including any dividends or dividend reinvestments).

How much is Virax Biolabs Group's stock price per share?

(NASDAQ: VRAX) Virax Biolabs Group stock price per share is $0.96 today (as of Feb 21, 2024).

What is Virax Biolabs Group's Market Cap?

(NASDAQ: VRAX) Virax Biolabs Group's market cap is $1.75M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Virax Biolabs Group's market cap is calculated by multiplying VRAX's current stock price of $0.96 by VRAX's total outstanding shares of 1,811,540.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.